Medical Condition News

RSS

NeuroDerm commences ND0611 Phase I/II trial to treat Parkinson's disease

NeuroDerm, Ltd. announced today the enrollment of the first group of patients in its Phase I/II clinical trial of ND0611, a new patch for the treatment of Parkinson's disease.

9 Mar 2011

U.S. FDA approves Hospira's docetaxel to treat variety of cancers

Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced U.S. Food and Drug Administration approval of docetaxel. The medication is a generic version of Sanofi-Aventis's Taxotere, and Hospira expects to launch the product later this month.

9 Mar 2011

Auxilium completes patient enrollment in XIAFLEX phase III trial against Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced it has reached the target enrollment for the double-blind placebo-controlled phase III program of XIAFLEX for the treatment of Peyronie's disease.

9 Mar 2011

Camp STAR to offer evidence-based therapy for children with ADHD

Camp STAR, the Chicago area's only summer camp offering evidence-based therapy for children with Attention Deficit/Hyperactivity Disorder and other behavioral, emotional and social difficulties, begins its fourth season in June.

9 Mar 2011

Older men have higher risk of melanoma: Australian study

Health experts warn that the rates of skin cancer – melanoma, is on the rise among elderly Victorians. This came out as new figures were released yesterday by Cancer Council Victoria that showed that Victorians aged over 55 accounted for two-thirds of melanoma diagnoses, and rural men were at highest risk. In 2008 a total of 2217 Victorians were diagnosed with melanoma and 279 people died. Skin cancer rates have increased by 400 per cent in the past 26 years among older males.

9 Mar 2011

Human Genome Sciences receives FDA approval for Benlysta to treat lupus

The U.S. Food and Drug Administration today approved Benlysta to treat patients with active, autoantibody-positive lupus who are receiving standard therapy, including corticosteroids, antimalarials, immunosuppressives, and nonsteroidal anti-inflammatory drugs.

9 Mar 2011

ERYtech Pharma completes patient enrollment in GRASPA Phase II trial against ALL

ERYtech Pharma announces the early completion of the enrollment and safety follow-up a Phase II clinical trial for GRASPA. This open-labeled trial introduced GRASPA in a first-line treatment for Acute Lymphoblastic Leukemia in patients older than 55 years.

9 Mar 2011

Atherotech announces Sponsorship Agreement with NLA

Aiming to boost advanced lipoprotein testing in lipid education and management, Atherotech Diagnostics Lab announces its Sponsorship Agreement with the National Lipid Association.

9 Mar 2011

Adamis submits APC-100 IND to FDA for treatment of prostate cancer

Adamis Pharmaceuticals Corporation announced today that it has recently submitted to the FDA an Investigational New Drug application for APC-100 to treat prostate cancer.

9 Mar 2011

Study finds passive smoking increases risk of still birth by 23%

Pregnant non-smokers who breathe in the second-hand smoke of other people are at an increased risk of delivering stillborn babies or babies with defects, a study led by researchers at The University of Nottingham has found.

9 Mar 2011

LUMEDX implements HealthView Chest Pain Management solution at Methodist hospitals

LUMEDX Corporation, a leading provider of fully integrated, vendor-neutral cardiovascular imaging and information systems, announced today that it has begun implementing the HealthView Chest Pain Management solution at five Methodist Healthcare facilities in San Antonio, Texas.

9 Mar 2011

ADVANTAGE, ITA to implement proprietary oncology decision-support platform

To improve outcomes and manage costs for members with cancer, ADVANTAGE Health Solutions, Inc. has contracted with ITA Partners to implement eviti - ITA's proprietary oncology decision-support platform - across their provider network.

9 Mar 2011

MD Solarsciences launches new sunscreen lotion at 2011 AAD meeting

A year after its launch, the first dermatologist-driven company dedicated to primary skin cancer protection and prevention introduced its newest solar protection product -- a much-anticipated tinted mineral gel sunscreen – at the 2011 AAD meeting in New Orleans.

9 Mar 2011

Vermillion's CA125 positive preliminary data against ovarian tumors presented at WCSGO

Vermillion, a molecular diagnostics company, today announced the presentation of positive preliminary data from its collaboration with Johns Hopkins University School of Medicine to identify biomarkers that improve on the specificity of CA125 for the identification of malignant ovarian tumors.

9 Mar 2011

BIOTRONIK's new ablation catheter is now available in Europe

BIOTRONIK SE Co. & KG, a leading manufacturer of cardiac devices, has announced that its innovative new ablation catheter, AlCath Flux eXtra Gold, is now available throughout Europe after receiving CE mark and successfully completing the premarket evaluation in Germany, Italy, Switzerland and several other European countries.

9 Mar 2011

Oral magnesium oxide is a safe treatment for children with chronic constipation

Magnesium-containing cathartics are commonly used to treat chronic constipation. Although hypermagnesemia is a rare clinical condition, it can occur as a side effect of increased intake of magnesium salts.

9 Mar 2011

MabCure presents ovarian cancer diagnostic blood test study results at SGO meeting

Biotechnology company MabCure, Inc. is presenting the results of its recently completed study on the diagnosis of ovarian cancer utilizing its proprietary monoclonal antibodies at the annual meeting of the Society of Gynecological Oncologists.

9 Mar 2011

Study supports DNA mismatch repair test for bowel cancer

Bowel cancer patients whose tumors contain defects in specific DNA repair systems are much less likely to experience tumour recurrence post surgery, results from a major clinical study have demonstrated.

9 Mar 2011

Wound Repair and Regeneration publishes positive findings from CXM's Matrix Phase 2b clinical study

Cardium Therapeutics today announced the publication of positive findings from the Company's Matrix Phase 2b clinical study.

9 Mar 2011

Collaborative care programs in hospitals reduce depression, anxiety in heart disease patients

Participants in the first hospital-initiated, low-intensity collaborative care program to treat depression in heart patients showed significant improvements in their depression, anxiety and emotional quality of life after 6 and 12 weeks, researchers report in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.

9 Mar 2011

Medical Condition News

NeuroDerm commences ND0611 Phase I/II trial to treat Parkinson's disease

U.S. FDA approves Hospira's docetaxel to treat variety of cancers

Auxilium completes patient enrollment in XIAFLEX phase III trial against Peyronie's disease

Camp STAR to offer evidence-based therapy for children with ADHD

Older men have higher risk of melanoma: Australian study

Human Genome Sciences receives FDA approval for Benlysta to treat lupus

ERYtech Pharma completes patient enrollment in GRASPA Phase II trial against ALL

Atherotech announces Sponsorship Agreement with NLA

Adamis submits APC-100 IND to FDA for treatment of prostate cancer

Study finds passive smoking increases risk of still birth by 23%

LUMEDX implements HealthView Chest Pain Management solution at Methodist hospitals

ADVANTAGE, ITA to implement proprietary oncology decision-support platform

MD Solarsciences launches new sunscreen lotion at 2011 AAD meeting

Vermillion's CA125 positive preliminary data against ovarian tumors presented at WCSGO

BIOTRONIK's new ablation catheter is now available in Europe

Oral magnesium oxide is a safe treatment for children with chronic constipation

MabCure presents ovarian cancer diagnostic blood test study results at SGO meeting

Study supports DNA mismatch repair test for bowel cancer

Wound Repair and Regeneration publishes positive findings from CXM's Matrix Phase 2b clinical study

Collaborative care programs in hospitals reduce depression, anxiety in heart disease patients

The CAR T Veteran: A Journey of Resilience, Remission, and Advocacy

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Latest News